Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLOXIN vs CHRONULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
FDA-approved: Adjunctive therapy in euthyroid patients with primary hypercholesterolemia (elevated LDL) who have not responded to diet and other measures.,Off-label: Treatment of hypothyroidism (though not preferred); investigational use for reducing cardiovascular risk.
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy)
50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.
10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.
Terminal elimination half-life is approximately 1-2 hours in euthyroid patients; may be prolonged in hypothyroidism or hepatic impairment.
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Primarily hepatic; undergoes deiodination and conjugation to glucuronides and sulfates. Hepatic clearance involves CYP450 enzymes, with a half-life of approximately 12-24 hours.
Not absorbed systemically; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Primarily renal excretion of conjugated metabolites (70-80% of dose); biliary/fecal excretion accounts for 10-20%; less than 5% excreted unchanged.
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Highly bound (>99%) to thyroxine-binding globulin (TBG), transthyretin, and albumin.
Negligible (<5%), primarily to albumin.
Apparent volume of distribution is 0.10-0.20 L/kg, reflecting extensive tissue binding and distribution.
Approximately 0.25 L/kg; distributes mainly into extracellular fluid.
Oral bioavailability is 50-80%, reduced by food, bile acid sequestrants, and certain drugs.
Oral: poorly absorbed; <3% reaches systemic circulation as intact lactulose; the remainder is metabolized by colonic bacteria.
No dose adjustment required for renal impairment as drug is hepatically cleared.
No dose adjustment required for renal impairment; caution in severe renal impairment due to electrolyte disturbances.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: reduce dose by 50-75% and monitor T4 closely.
No adjustment needed; used in hepatic encephalopathy at higher doses.
Neonates: 10-15 mcg/kg/day orally. Infants: 5-10 mcg/kg/day. Children: 2-5 mcg/kg/day. Adjust based on T4 levels.
Infants: 2.5-5 m L orally once daily; Children 1-5 years: 5-10 m L once daily; Children 6-12 years: 10-15 m L once daily; Adolescents: 15-30 m L once daily; adjust based on response.
Start at 25 mcg/day orally, titrate slowly (every 4-6 weeks) due to increased sensitivity and risk of cardiac adverse effects.
Start at low end of dosing range (10-15 m L once daily) due to increased risk of electrolyte imbalance and dehydration; monitor fluid/electrolyte status.
None specified in FDA labeling.
None.
Cardiac toxicity: Increased risk of arrhythmias, angina, and myocardial infarction, especially in patients with pre-existing cardiovascular disease.,Hyperthyroidism: Can induce thyrotoxicosis if dose is too high or in patients with iodine deficiency.,Drug interactions: Enhances effect of oral anticoagulants (reduce warfarin dose); decreases effect of antidiabetic medications; alters response to digitalis.,Use in pregnancy: Category X – contraindicated due to teratogenic effects.
Electrolyte disturbances (e.g., hypernatremia, hypokalemia) with prolonged use or high doses,Diarrhea may cause fluid and electrolyte loss,Risk of colonic distention or fecal impaction,Use caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (contains galactose and lactose)
Absolute: Euthyroid patients with pre-existing cardiovascular disease (e.g., recent MI, unstable angina, significant arrhythmias).,Absolute: Thyrotoxicosis or iodine deficiency.,Absolute: Pregnancy (Category X).,Relative: Renal or hepatic impairment; concomitant use of anticoagulants (requires close monitoring).
Patients with galactosemia,Intestinal obstruction,Known hypersensitivity to lactulose
High-fiber foods (e.g., bran, whole grains) may reduce absorption; take levothyroxine separately. Soy-containing products (e.g., tofu, soy milk) and grapefruit juice can alter absorption. Consume these at least 4 hours apart from dosing. Avoid taking with walnuts, cottonseed meal, or concentrated iron-rich foods.
No specific food interactions, but avoid concurrent use with other laxatives. Ensure adequate fluid intake to reduce risk of hypernatremia.
CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of congenital defects; second and third trimester exposure may impair fetal thyroid function and development. Risk cannot be excluded.
Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not conducted. Based on lack of systemic absorption, risk to fetus is low across all trimesters.
Excretion into human milk is unknown. Due to potential for serious adverse effects in nursing infants, including interference with thyroid function, breastfeeding is contraindicated. M/P ratio not determined.
Lactulose is not absorbed orally; therefore, excretion into breast milk is negligible. Considered compatible with breastfeeding; no M/P ratio available due to lack of systemic absorption.
Pregnancy increases thyroid hormone requirements. Dextrothyroxine is not recommended due to lack of safety data. If used, dose may need increase based on TSH monitoring. Hyperthyroid effects may necessitate dose reduction. Not a standard therapy; levothyroxine is preferred.
No dose adjustment required during pregnancy. Pharmacokinetics of lactulose are unchanged due to lack of systemic absorption. Use standard dosing for constipation (15-30 m L daily, titrated to effect).
CHOLOXIN (sodium levothyroxine) is a synthetic T4 thyroid hormone. Monitor TSH levels 6-8 weeks after dose changes; target TSH 0.5-2.5 m IU/L for most adults. Administer on empty stomach, 30-60 minutes before breakfast, with water. Avoid concurrent calcium, iron, or antacids within 4 hours. Dose adjustments needed in pregnancy, with T4 dose increase by 30-50% typically. Check for drug interactions with amiodarone, oral contraceptives, and tyrosine kinase inhibitors.
Chronulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Onset of action for constipation is 24-48 hours; monitor for electrolyte disturbances (hypernatremia) with prolonged use. Do not use with other laxatives in acute abdomen. For hepatic encephalopathy, titrate to 2-3 soft stools daily.
Take levothyroxine on an empty stomach, at least 30-60 minutes before breakfast.,Take with a full glass of water, not with other beverages.,Do not take within 4 hours of calcium or iron supplements, antacids, or sucralfate.,Consistency is key: take the same brand and dose daily; do not switch brands without consulting your provider.,Report symptoms of hyperthyroidism (palpitations, anxiety, weight loss) or hypothyroidism (fatigue, cold intolerance, constipation) promptly.,Do not stop or change dose without talking to your doctor; lab monitoring is required.,If you miss a dose, take it as soon as remembered, but skip if near next dose; do not double.,Inform all healthcare providers you are taking this medication, especially before surgery or starting new meds.
May take 24-48 hours to produce a bowel movement; do not use if you have abdominal pain, nausea, or vomiting.,Mix with fruit juice, milk, or water to improve taste.,Store at room temperature; do not freeze.,Report excessive diarrhea or electrolyte imbalance symptoms (muscle cramps, weakness).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLOXIN vs CHRONULAC, answered by our medical review team.
CHOLOXIN is a Thyroid Hormone Analog that works by Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.. CHRONULAC is a Osmotic Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLOXIN and CHRONULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLOXIN is: 50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.. The standard adult dose of CHRONULAC is: 10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLOXIN and CHRONULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLOXIN is classified as Category C. CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of . CHRONULAC is classified as Category C. Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.